NEW YORK (GenomeWeb News) – Seeking a share of a market estimated at around $1 billion, GenomeDx plans to launch its first test aimed at prostate cancer during the first half of this year, CEO Doug Dolginow said.

Based on whole-genome analysis to profile RNA expression signatures, the test measures the aggressiveness of prostate cancer in patients who have had a prostatectomy. Typically, after the surgery, a doctor will monitor a patient's prostate-specific antigen levels to evaluate whether the cancer has returned and whether follow-up treatment is needed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.